Tyra Biosciences (NASDAQ:TYRA) Now Covered by Piper Sandler

Equities research analysts at Piper Sandler began coverage on shares of Tyra Biosciences (NASDAQ:TYRA - Get Free Report) in a research report issued to clients and investors on Wednesday. The firm set an "overweight" rating and a $33.00 price target on the stock. Piper Sandler's price objective suggests a potential upside of 235.60% from the stock's current price.

A number of other research firms also recently commented on TYRA. HC Wainwright reaffirmed a "buy" rating and set a $30.00 target price on shares of Tyra Biosciences in a report on Monday, March 31st. Wedbush reissued an "outperform" rating and issued a $30.00 price target on shares of Tyra Biosciences in a report on Friday, March 28th. Six research analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has a consensus rating of "Buy" and an average price target of $30.83.

Tyra Biosciences Stock Down 1.5%

NASDAQ:TYRA traded down $0.15 during trading hours on Wednesday, reaching $9.83. 10,498 shares of the stock were exchanged, compared to its average volume of 261,066. The firm has a 50 day simple moving average of $9.52 and a 200-day simple moving average of $12.74. Tyra Biosciences has a 52 week low of $6.42 and a 52 week high of $29.60. The stock has a market capitalization of $522.03 million, a P/E ratio of -6.10 and a beta of 1.17.

Tyra Biosciences (NASDAQ:TYRA - Get Free Report) last released its earnings results on Thursday, May 8th. The company reported ($0.47) EPS for the quarter, topping analysts' consensus estimates of ($0.49) by $0.02. As a group, analysts expect that Tyra Biosciences will post -1.57 earnings per share for the current year.

Institutional Trading of Tyra Biosciences

A number of hedge funds and other institutional investors have recently modified their holdings of TYRA. China Universal Asset Management Co. Ltd. bought a new stake in shares of Tyra Biosciences in the 4th quarter worth $149,000. Rhumbline Advisers raised its stake in shares of Tyra Biosciences by 4.1% in the 4th quarter. Rhumbline Advisers now owns 26,202 shares of the company's stock worth $364,000 after buying an additional 1,027 shares in the last quarter. Bank of New York Mellon Corp raised its stake in shares of Tyra Biosciences by 5.2% in the 4th quarter. Bank of New York Mellon Corp now owns 45,007 shares of the company's stock worth $626,000 after buying an additional 2,221 shares in the last quarter. US Bancorp DE bought a new stake in shares of Tyra Biosciences in the 4th quarter worth $50,000. Finally, Alta Partners Management Company L.P. bought a new stake in shares of Tyra Biosciences in the 4th quarter worth $56,716,000. Institutional investors own 84.14% of the company's stock.

About Tyra Biosciences

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.